

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-173) LETETRESGENE AUTOLEUCEL

PRONUNCIATION let" e tres' jeen aw" toe loo' sel

THERAPEUTIC CLAIM Antineoplastic

PRODUCT DESCRIPTION

Autologous CD4+ and CD8+ T cells, transduced with a non-replicating human immunodeficiency virus (HIV)-derived self-inactivating (SIN) vector that comprises a 5' LTR (RSV\*-R-U5) and a 3' U3 deleted LTR (U5-R-HIV-1Delta 3'LTR), encoding an affinity enhanced NY-ESO-1 (autoimmunogenic cancer/testis antigen NY-ESO-1, CTAG1A, L antigen family member 2, LAGE-2) specific T cell receptor (TCR), under the control of elongation factor 1 alpha (EF1a) promoter. The vector is pseudo typed with vesicular stomatitis virus glycoprotein-G (VSV-G).

\* RSV: Rous sarcoma virus

TRADEMARK None as yet

SPONSOR GlaxoSmith Kline

CODE DESIGNATION GSK3377794

UNII B5ME4ZU4BS

WHO NUMBER 10866

SCS